Update on Trichodynia, a Challenge for Dermatologists
September 2024
in “
Actas Dermo-Sifiliográficas
”
New to Botox? There is a guide in the encyclopedia. Read the guide → Studysummary This study discusses trichodynia, a painful scalp condition often linked to various forms of alopecia and psychiatric comorbidities, highlighting its clinical diagnosis, lack of specific treatments, and suggesting the need for more research to explore effective therapies. Our plain-language summary of this paper — not a Tressless recommendation.
Trichodynia, characterized by scalp pain often associated with various types of alopecia, remains a therapeutic challenge for dermatologists. Initially described in 1996 in patients with telogen effluvium, it is now linked to androgenic alopecia, scarring alopecia, alopecia areata, trichotillomania, and chemotherapy-induced alopecia. It is also frequently associated with psychiatric conditions like depression and anxiety, particularly in women. The pathogenesis is unclear but may involve substance P, psychiatric comorbidities, and perifollicular inflammation. Diagnosis is clinical and exclusionary, with no specific treatments available. Potential therapies include botulinum toxin A, antidepressants, neuromodulators, propranolol, corticosteroids, and topical cannabinoids. More research is needed to develop effective treatments.
